Ozempic increases the risk of ‘silent cancer’ that increases among young people, studies finds

Ozempic and similar weight loss drugs can increase the risk of kidney cancer, a large study suggests.

But the fat -feeling photos lower the risk of more than a dozen other cancers, which means that the benefits still outweigh the risks.

The findings come as part of the world’s largest study of weight loss drug users who looked at 86,000 obese or overweight patients who were followed for up to ten years.

In general, researchers discovered that users had a 17 percent lower risk of getting 16 cancers compared to people with a comparable weight that the medicines have not used.

This was in particular marked for endometrial cancers, where the risk was reduced by 15 percent and ovarian cancer, where the risk was reduced by 47 percent.

Both cancers are strongly linked to obesity.

But kidney cancer was a biter. Patients who used weight loss medicines were more likely to be diagnosed.

Dr. Hao Dai, a health scientist at Indiana University who led the research, emphasized that the study was observational and did not show that drugs for weight loss such as Ozempic cause kidney cancer.

But he told the Daily Mail that the results were ‘concerning’ and underlined the need for further research.

Real Housewives of New Jersey star Dolores Catania, depicted in 2018 and 2024, suffered nausea while making weight loss shots. A theory is that side effects of illness and vomiting can cause repeated attacks of acute kidney injury, which increases the risk of cancer

Meghan Trainor has publicly stated that she used Ozempic before she continues with other drugs for weight loss

Kidney cancer is often called a ‘silent’ cancer because it can grow without causing clear symptoms at an early stage.

When the symptoms appear, doctors say it is often too late. The chances of survival fall when the tumor has spread elsewhere in the body.

Symptoms can be blood in the urine, low back pain or a palpable mass.

In the new study, scientists recruited 43,000 patients who had used drugs for weight loss and corresponded to 43,000 control patients who had the same characteristics but were not in the medicines.

Data comes from the Florida+ database, which stores data about the medical history of millions of patients in Florida.

Participants had an average age of 52 and almost seven in 10 were feminine.

Nobody had a cancer diagnosis at the start of the investigation.

Half took the drugs for type 2 diabetes and half took them to treat their obesity.

During an average of three years, researchers registered 1,900 cases of 16 different cancers in the group.

Of these, 891 were registered in patients who used weight loss drugs, while 1,022 were registered in people who did not use the medicines.

For kidney cancer, however, 83 cases were registered in patients with GLP-1 drugs compared to 58 cases in the control group.

Researchers said they intend to follow the patients longer to confirm the data.

But their results are in line with other research into weight loss medicines and kidney cancer.

A Study published in July last year In 1.6 million type 2, diabetics found that patients who used Ozempic drugs had a 54 percent higher risk of suffering from kidney cancer compared to diabetics who took the cheap diabetes drug metetformin.

Another study published in May In 1.2 million patients with type 2 diabetes, a 45 percent higher risk of the diagnosis of kidney cancer in patients in the drug compared to patients taking metformin.

Dr. Neil Iyengar, an onoClogist at Memorial Sloan Kettering Cancer Center in New York, who was not involved in the latest study, The Daily Mail said that he did not fully bought the potential link with kidney cancer, which emphasized that other research has shown that GLP-1 media is actually protecting niters.

“The problem is that we still collect GLP-1 data at a very early stage that will give us a mixed result,” he said.

“However, we need more data to tackle this potential problem with kidney cancer.”

The latest study was presented at the annual conference of the American Clinical Society of Oncology in Chicago, Illinois, the largest cancer conference in the world.

Dr. Dai is also careful with the interpretation of the findings too much.

“We still have to do an observational study to confirm that these drugs increase the risk,” he said this website.

‘But from my point of view it is possible that the drugs increase the risk of some types of kidney cancer. However, we do not know and have to do more research. ‘

A slide he shared during his presentation read: “Monitoring for kidney cancer: observed trends in the direction of increased kidney cancer risk emphasizes the need for continuous supervision and further research.”

A theory is that the common side effects of the drug, including serious nausea, vomiting and dehydration, can cause repeated attacks of acute kidney injury.

Over time, that stress can damage the kidney tissue and increase the risk of mutations that lead to cancer.

Another point of concern is that the kidneys contain GLP-1 receptors. These are the same receptors Ozempic goals to regulate blood sugar levels and to maintain people.

Some scientists wonder if constantly stimulating these receptors can cause cells in the kidneys to get out of hand, although this stays speculative and has not been proven in humans.

Quick weight loss and dramatic metabolic shifts caused by the drug can also play a role, which may make the body’s immune response to be changed or reveal existing kidney problems.

Kidney cancer is estimated as the seventh most common cancer in the US, with around 80,000 cases diagnosed in the country every year.

In the UK there are almost 14,000 new diagnoses and 4,700 deaths per year of the disease.

Kidney cancer has a good survival percentage if it is diagnosed at an early stage, with 75 percent of patients living for five years or more.

But if the cancer is diagnosed when it has spread to other parts of the body, it drops to 18 percent.

The most common type of kidney cancer, kidney cell carcinoma, accounts for around 90 percent of adult kidney cancer.

Although age is a risk factor – most patients are diagnosed over 60 – there is an additional increase in cases in younger adults.

People born in 1990 experienced kidney cancer percentages two to three times higher than born in 1955.

Some researchers partially attribute this increase to improved imaging and earlier detection, but environmental factors, obesity and high blood pressure can also play a role.